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ers knowledge of ﬁbromyalgia reveals no difference regarding the
deﬁnition of this pathology and some mild differences appears
in their knowledge of the ACR criteria and their appreciation of
the associated symptoms (the frequency of widespread pain and
joint swelling in particular). It is surprising how the knowledge
GPs in France and Portugal have of FM is closer than between
GPs and Rheumatologists in each country.
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OBJECTIVES: To assess the cost-effectiveness of Palivizumab, a
prevention against respiratory syncytial virus (RSV) infections in
infants at high risk, such as premature babies, infants with bron-
chopulmonary dysplasia (BPD), and children with congenital
heart disease (CHD). METHODS: A decision tree model was
used to estimate the cost-effectiveness of Palivizumab in high-
risk children. The data sources included published literature, the
Palivizumab clinical trials, ofﬁcial price/tariff lists and national
population statistics. The primary perspective of the study was
that of the society, which included cost of the complications
asthma and wheezing. RESULTS: The use of Palivizumab results
in an ICER of €12,728/QALY without discounting for effective-
ness, which increases to €20,236/QALY after discounting for
effectiveness in the prematurity/BPD indications. In the CHD
indication the use of Palivizumab results in an ICER of
€4256/QALY without discounting for effectiveness and
€7067/QALY after discounting for effectiveness. Sensitivity
analyses conﬁrmed the robustness of the model. CONCLU-
SION: This study showed that Palivizumab is a cost-effective
treatment against RSV in infants at high risk: the use of
Palivizumab results in positive short and long-term health eco-
nomic beneﬁts to the society and health authorities.
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OBJECTIVE: The objective of the study was the estimation of
the actual hospitalization costs of two neonatal intensive care
units of university of Athens. METHODS: The study was based
on retrospective data gathered from the records of 70 neonates
who were hospitalized at the NICUs of Alexandra’s obstetric and
Aglaia Kyriakou pediatric hospitals of Athens, with admission
dates between February and April 2004 until their discharge
from the hospital. Clinical data derived from medical records,
while economic data from each hospital’s administrative and
ﬁnancial department. Regression analysis was performed with
SPSS program in order to ﬁnd the correlation between the cost
and birthweight and other parameters. The mean daily treatment
cost was estimated according to: birth weight and gestational age
of the neonates as well as Length of Stay in NICU and Interme-
diate level II until their discharge from hospital. Direct cost
analysis was based on cost of personnel, cost of supplies, med-
ication, parental feeding, laboratory and imaging tests, cost of
infrastructure, hotel services and various other on-site costs. The
economic analysis did not include the depreciation of capital
assets. The prices used for the analysis were based on Greek NHS
prices, expressed in €2004. RESULTS: The mean daily actual
cost per infant in the NICU of Alexandra was 207 euro and for
intermediate level II €121. The mean daily actual cost per infant
in NICU for Aglaia Kyriakou hospital was 511€ and for inter-
mediate level II €231. The mean length of stay (LOS) in the
NICU and Intermediate level II of Alexandra was 17.22 and
24.16 days respectively. The mean LOS in the NICU and Inter-
mediate level II of A.Kyriakou was 8.5 and 11.5 days respec-
tively. CONCLUSION: Estimates of the economic costs of
preterm birth can be informative to decision-makers and facili-
tates quality improvement efforts used in neonatal care.
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OBJECTIVES: To establish a model that estimates a preference-
based measure of social participation for children between 8 and
18 years from the Handicap Scale for Children (HSC) classiﬁca-
tion system. METHODS: A sub-sample of the social participa-
tion vignettes of the HSC classiﬁcation system was valued on a
VAS scale by a representative sample of 249 persons of the
general Dutch population aged 18 years onwards. Several models
based on a full state (econometric) method were considered in
order to extrapolate the available valuations for the sub-sample
to all possible vignettes. RESULTS: The best ﬁtted model
assumes that the VAS scale and the scale of the ﬁve dimensions
of the HSC (mobility, physical, daily activities, social integration
and orientation) are linear, includes an interaction for mobility
with physical independence, orientation with mobility, physical
independence, daily activities and social integration, and
accounts for clustering by respondents. The measurement prop-
erties of the weighted scoring of the best ﬁtted model improves
upon models which assume an ordinal scale of the ﬁve dimen-
sions, do not include interactions and/or do not account for clus-
tering. The model that simply sums up the levels of each
dimension provides systematic errors for the preferences. CON-
CLUSIONS: We obtained a preference-based measure for social
participation for children between 8 and 18 years that can be
used for assessing need, for quality assurance and for evaluating
interventions on a group level aiming to increase social partici-
pation in children with chronic illnesses.
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OBJECTIVES: The primary objective was to determine the cost-
effectiveness acceptability of targeted (TA) versus universal
assessment (UA) and geriatric team (GM) versus primary care
(PC) management models. METHODS: The primary effective-
ness measure was life years gained (LYGs). The perspective was
societal. The primary analysis used a 3-year timeframe. Resource
use data and survival were collected within a multi-centre, cluster
